Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pulmonology
•
Pulmonary Hypertension
•
Diffuse Parenchymal Lung Disease
•
General Pulmonary
What strategies are effective for managing cough in patients receiving inhaled treprostinil?
Related Questions
Are there certain clinical features that help you choose between benralizumab and mepolizumab for EGPA in clinical practice?
Are there benefits to adding IL5/IL5 receptor blockade in patients with vasculitic manifestations of EGPA?
Do you utilize cytokine panels to guide treatment of patients with EGPA?
What is your approach to treatment in a patient with radiographic UIP but pathologic evidence of both fibrotic NSIP and UIP?
Does the presence of a bloody aspirate reduce the diagnostic yield of EBUS bronchoscopy, and if so, what strategies can be employed to minimize its occurrence?
When interpreting pulmonary function tests, do you routinely distinguish between hyperinflation and gas trapping?
How do you mitigate risk when performing bronchoscopy in hypoxic patients requiring high levels of supplemental oxygen?
How often are you performing CT screening in CVID patients to screen for ILD?
What is the role of inebilizumab in the maintenance treatment of IgG4-related disease?
What factors would encourage you to choose abatacept vs tocilizumab in a patient with RA-ILD with a UIP pattern of pulmonary fibrosis?
